Skip to content
Riskpilot
← Back to search
Sign in
Get full access
STIPE Therapeutics ApS
APS
Bankrupt
Advertising protection
CVR 39691175
Axeltorv 2, 1609
København V
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2018 · 7 years old
1 employees
Monitor
Share
Denmark
/
Companies
/
Research and experimental development on natural sciences and engineering
/
STIPE Therapeutics ApS
Overview
Financials
People & ownership
Related companies
Loading company…
People & ownership
Management
Actively employed in the business
Name
Role
Member since
Former (3)
PJ
Preben Jakobsen
Unofficial title
Unofficial title
2024 – 2026
CE
Claus Elsborg Olesen
Management
Management
2018 – 2024
MR
Martin Roelsgaard Jakobsen
Management
Management
2018 – 2021
Board of directors
Non-executive oversight
Name
Role
Member since
Former (8)
MD
Morten Døssing
Board of Directors
Board of Directors
2019 – 2024
JS
John Stephen Cassidy
Board of Directors
Board of Directors
2021 – 2021
CS
Christian Schetter
Chairman
Chairman
2019 – 2024
RH
Regina Hodits
Board of Directors
Board of Directors
2020 – 2024
MD
Mark David Chin
Board of Directors
Board of Directors
2021 – 2023
NR
Natalie Rose Sacks
Board of Directors
Board of Directors
2020 – 2023
SV
Sten Verland
Board of Directors
Board of Directors
2019 – 2024
JL
Jonathan Leslie Tobin
Board of Directors
Board of Directors
2019 – 2021
Shareholders
As of last annual report
Shareholder
Type
Ownership
Votes
Since
Novo Holdings A/S
Company
25–33.32%
25–33.32%
2023
Sunstone Life Science Ventures Fund IV K/S
Company
20–24.99%
20–24.99%
2023
Wellington Partners V Life Sciences Fund
Individual
20–24.99%
20–24.99%
2023
MR Jakobsen Holding ApS
Company
10–14.99%
10–14.99%
2021
CLAUS OLESEN HOLDING ApS
Company
5–9.99%
5–9.99%
2021
Arix Bioscience Holdings Limited
Individual
20–24.99%
20–24.99%
2021
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
More on STIPE Therapeutics ApS
Overview →
Headline figures, risk assessment and company summary
Financials & key figures →
Revenue, EBITDA, balance sheet and 5-year trend
Related companies →
Corporate hierarchy, parent and subsidiary network